CTI wins $20 million in financing
PET developer CTI received a $20-million boost this month from venture capital firm First Union Capital Partners (FUCP). The Knoxville, TN, company will use the capital to underwrite its own growth efforts, as well as those of its affiliate, PETNet
PET developer CTI received a $20-million boost this month from venture capital firm First Union Capital Partners (FUCP). The Knoxville, TN, company will use the capital to underwrite its own growth efforts, as well as those of its affiliate, PETNet Pharmaceutical Services of Norcross, GA. With PETNet, CTI plans to focus on developing its lutetium oxyortho-silicate (LSO) detector material, and new PET-compound manufacturing and distribution centers, according to Terry Douglass, president of CTI.
Charlotte, NC-based FUCPs funding feeds the momentum CTI has generated in the past year. In June, the company won interest at the Society of Nuclear Medicine show in Los Angeles when Siemens Medical Systems displayed images collected by a combination CT/PET scanner developed by CTI PET Systems, the PET joint venture between Siemens and CTI (SCAN 6/24/98). Dr. Henry Wagner of Johns Hopkins in Baltimore named a Siemens CT/PET image as Image of the Year in his post-SNM roundup speech. And in July, CTI acquired Advanced Crystal Technology from Nihon Kessho Koogaku, a subsidiary of Mitsui Mining and Smelting, a deal that gives CTI increased access to bismuth germinate (BGO), a key detector component in PET devices (SCAN 8/4/99).
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
